SLC12A2 and Ventriculomegaly: Specifically, AAV2/5-mediated overexpression of NKCC1—which has shown ventricle-decreasing effects—could represent a targeted strategy to alleviate AAV-induced ventriculomegaly (Sadegh et al. 2023; Xu et al. 2021).